These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 19519286)

  • 21. Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options?
    Bourhis J; Lefebvre JL; Vermorken JB
    Eur J Cancer; 2010 Jul; 46(11):1979-89. PubMed ID: 20561781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidermal growth factor receptor directed therapy in head and neck cancer.
    Choong NW; Cohen EE
    Crit Rev Oncol Hematol; 2006 Jan; 57(1):25-43. PubMed ID: 16207530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging role of EGFR-targeted therapies and radiation in head and neck cancer.
    Song J; Chen C; Raben D
    Oncology (Williston Park); 2004 Dec; 18(14):1757-67; discussion 1767, 1771-2, 1777. PubMed ID: 15700625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacotherapy of head and neck squamous cell carcinoma.
    Pan Q; Gorin MA; Teknos TN
    Expert Opin Pharmacother; 2009 Oct; 10(14):2291-302. PubMed ID: 19663637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of endothelial cell network formation in vitro by molecular signaling of head and neck squamous cell carcinoma (HNSCC) exposed to cetuximab.
    Jouan-Hureaux V; Boura C; Merlin JL; Faivre B
    Microvasc Res; 2012 Mar; 83(2):131-7. PubMed ID: 21820450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy of combined treatment with cetuximab (erbitux) and radiation therapy in patients with head and neck cancer.
    Koukourakis G; Kouloulias V; Koukourakis M; Kouvaris J; Zacharias G; Gouliamos A
    J BUON; 2009; 14(1):19-25. PubMed ID: 19373942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of antiangiogenic agents in the treatment of head and neck cancer.
    Denaro N; Russi EG; Colantonio I; Adamo V; Merlano MC
    Oncology; 2012; 83(2):108-16. PubMed ID: 22777379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.
    Rivera F; García-Castaño A; Vega N; Vega-Villegas ME; Gutiérrez-Sanz L
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1421-8. PubMed ID: 19828002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined molecular targeted drug therapy for EGFR and HER-2 in head and neck squamous cell carcinoma cell lines.
    Kondo N; Tsukuda M; Sakakibara A; Takahashi H; Hyakusoku H; Komatsu M; Niho T; Nakazaki K; Toth G
    Int J Oncol; 2012 Jun; 40(6):1805-12. PubMed ID: 22344385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular-targeted therapy of head and neck squamous cell carcinoma: beyond cetuximab-based therapy.
    Machiels JP; Schmitz S
    Curr Opin Oncol; 2011 May; 23(3):241-8. PubMed ID: 21358328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck?
    Bernier J; Schneider D
    Eur J Cancer; 2007 Jan; 43(1):35-45. PubMed ID: 17098420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A multidisciplinary approach to squamous cell carcinomas of the head and neck: an update.
    Bernier J
    Curr Opin Oncol; 2008 May; 20(3):249-55. PubMed ID: 18391622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer.
    Astsaturov I; Cohen RB; Harari P
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1179-93. PubMed ID: 17020453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incorporation of molecularly targeted agents in the primary treatment of squamous cell carcinomas of the head and neck.
    Bernier J
    Hematol Oncol Clin North Am; 2008 Dec; 22(6):1193-208, ix. PubMed ID: 19010268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidermal growth factor receptor biology in head and neck cancer.
    Kalyankrishna S; Grandis JR
    J Clin Oncol; 2006 Jun; 24(17):2666-72. PubMed ID: 16763281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transforming growth factor alpha stimulation of mucosal tissue cultures from head and neck squamous cell carcinoma patients increases chemoresistance to cisplatin.
    Baumeister P; Reiter M; Schwenk-Zieger S; Harréus U
    Chemotherapy; 2010; 56(4):268-74. PubMed ID: 20693797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
    Vermorken JB; Trigo J; Hitt R; Koralewski P; Diaz-Rubio E; Rolland F; Knecht R; Amellal N; Schueler A; Baselga J
    J Clin Oncol; 2007 Jun; 25(16):2171-7. PubMed ID: 17538161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence-based radiation oncology in head and neck squamous cell carcinoma.
    Corvò R
    Radiother Oncol; 2007 Oct; 85(1):156-70. PubMed ID: 17482300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Chemoradiotherapy in head and neck squamous cell carcinoma: focus on targeted therapies].
    Bozec A; Thariat J; Bensadoun RJ; Milano G
    Cancer Radiother; 2008 Jan; 12(1):14-24. PubMed ID: 18248834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck.
    Bernier J
    Nat Clin Pract Oncol; 2008 Dec; 5(12):705-13. PubMed ID: 18825142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.